Related Experiment Video

Updated: Oct 19, 2025

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention

Yong-Hoon Yoon1, Jung-Min Ahn2, Do-Yoon Kang2

  • 1Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, South Korea.

JACC. Cardiovascular Interventions
|September 24, 2021
PubMed

Insights

Elevated lipoprotein(a) [Lp(a)] levels increase the risk of recurrent ischemic events after percutaneous coronary intervention (PCI). This finding supports further research into Lp(a)-lowering therapies for secondary prevention in PCI patients.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Preventive Medicine

Background:

  • Elevated lipoprotein(a) [Lp(a)] is a known risk factor for atherosclerotic cardiovascular disease.
  • Understanding Lp(a)'s role in post-PCI outcomes is crucial for secondary prevention.

Purpose of the Study:

  • To evaluate the association between high Lp(a) levels and the risk of recurrent ischemic events in patients who underwent percutaneous coronary intervention (PCI).

Main Methods:

  • A prospective registry of 12,064 patients with baseline Lp(a) measurements who underwent PCI between 2003 and 2013.
  • Primary outcomes included cardiovascular death, myocardial infarction, and ischemic stroke, with a median follow-up of 7.4 years.

Main Results:

  • Patients with high Lp(a) (>30 mg/dL) showed a significantly higher incidence of primary outcomes (aHR: 1.17; P = 0.004).
  • Increased risk of recurrent ischemic events and revascularization was observed in the high Lp(a) group, even with statin treatment.

Conclusions:

  • High Lp(a) levels are significantly associated with recurrent ischemic events in patients post-PCI.
  • These findings suggest Lp(a)-lowering therapies could be beneficial for secondary prevention in this patient population.
Abstract

Keywords:
coronary diseaselipoprotein (a)prognosisstent

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.5K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
75
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
84
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
67
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
66
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
401